Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4

Moomoo News · Nov 14, 2024 20:34 · Ratings

Piper Sandler analyst Allison Bratzel maintains $Akebia Therapeutics (AKBA.US)$ with a buy rating, and maintains the target price at $4.

According to TipRanks data, the analyst has a success rate of 72.3% and a total average return of 28.0% over the past year.

AnalystRecentRatingAutoNews_201194_20241114_fa3a59c0d92b8a16ce10a5c6b9b2b6a5864a0988_1731591089300121_mm_en

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4

Risk Disclaimer